Search Result
Results for "
Amyloid β-protein
" in MedChemExpress (MCE) Product Catalog:
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1474A
-
Amyloid β-protein (22-35) (TFA)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
-
- HY-P4883
-
-
-
- HY-P4884
-
-
-
- HY-P4887
-
-
-
- HY-P4892
-
-
-
- HY-P4894
-
-
-
- HY-P3793
-
|
Amyloid-β
|
Neurological Disease
|
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity .
|
-
-
- HY-P4886
-
|
Amyloid-β
|
Neurological Disease
|
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .
|
-
-
- HY-P1474
-
Amyloid β-protein (22-35)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
-
- HY-P1051
-
Amyloid β-protein (12-28)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .
|
-
-
- HY-P1051A
-
Amyloid β-protein (12-28) (TFA); Amyloid Beta-Peptide (12-28) (human) TFA; β-Amyloid protein fragment(12-28) TFA
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research .
|
-
-
- HY-P1046
-
Amyloid β-protein (1-15)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
|
-
-
- HY-P1466
-
Amyloid β-protein (1-16)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
|
-
-
- HY-P1468
-
Amyloid β-protein (1-28)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
|
-
-
- HY-P3858
-
|
Amyloid-β
|
Neurological Disease
|
(D-Asp1)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .
|
-
-
- HY-P3859
-
|
Amyloid-β
|
Neurological Disease
|
Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) can be used in research of Alzheimer's disease .
|
-
-
- HY-P4640
-
-
-
- HY-P3845
-
|
Amyloid-β
|
Neurological Disease
|
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation .
|
-
-
- HY-P3846
-
|
Amyloid-β
|
Neurological Disease
|
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .
|
-
-
- HY-P3860
-
-
-
- HY-P4585
-
|
Amyloid-β
|
Neurological Disease
|
(Gln22)-Amyloid β-Protein (1-42) is a Dutch mutation (E22Q) form of β-Amyloid (1-42) (HY-P1363). (Gln22)-Amyloid β-Protein (1-42) exhibits enhanced fibrillogenic and pathogenic properties .
|
-
-
- HY-P3781
-
|
Amyloid-β
|
Neurological Disease
|
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .
|
-
-
- HY-P4788
-
|
Amyloid-β
|
Neurological Disease
|
Acetyl-Amyloid β-Protein (1-6) amide is a hexapeptide that contains a potential copper(II) binding site. Acetyl-Amyloid β-Protein (1-6) amide can be used for research of Alzheimer's disease and related disorders .
|
-
-
- HY-P4882
-
|
Amyloid-β
|
Neurological Disease
|
(Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
|
-
-
- HY-P3783
-
-
-
- HY-P4882A
-
|
Amyloid-β
|
Neurological Disease
|
(Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
|
-
-
- HY-P4391
-
-
-
- HY-P4861
-
|
Amyloid-β
|
Others
|
Biotinyl-Ahx-Amyloid β-Protein (1-42) is abiotinylated β-Amyloid (1-42), human (TFA) (HY-P1363).
|
-
-
- HY-P3782
-
-
-
- HY-P1468F
-
Biotin-Amyloid β-protein (1-28)
|
Amyloid-β
|
Others
|
Biotin-β-amyloid (1-28) (Biotin-amyloid β-protein (1-28)) is abiotinylated β-Amyloid (1-28) (HY-P1468).
|
-
-
- HY-P3780
-
|
Amyloid-β
|
Neurological Disease
|
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .
|
-
-
- HY-P3908
-
|
Amyloid-β
|
Neurological Disease
|
FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 monomer peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .
|
-
-
- HY-N12321
-
|
Others
|
Metabolic Disease
|
2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .
|
-
-
- HY-P1468F1
-
5-FAM-Amyloid β-protein (1-28)
|
Amyloid-β
|
Others
|
5-FAM-β-Amyloid (1-28) is afluorescently labeled β-Amyloid (1-28) (HY-P1468).
|
-
-
- HY-P2551
-
|
Amyloid-β
|
Neurological Disease
|
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-?-(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via?post-translational processing of amyloid precursor protein (APP) .
|
-
-
- HY-P1522
-
-
-
- HY-19369
-
L-685,458
|
γ-secretase
Apoptosis
|
Neurological Disease
Cancer
|
L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC50s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .
|
-
-
- HY-D1443
-
(trans,trans)-1-Bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene
|
Amyloid-β
|
Others
|
BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease .
|
-
-
- HY-N0931
-
CAY-10683
|
HDAC
Amyloid-β
|
Neurological Disease
Cancer
|
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .
|
-
-
- HY-159083
-
|
Amyloid-β
|
Neurological Disease
|
DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of Aβ and tau protein and disaggregate the formed Aβ and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease .
|
-
-
- HY-146140
-
|
Amyloid-β
|
Neurological Disease
|
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .
|
-
-
- HY-146139
-
|
Amyloid-β
|
Neurological Disease
|
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .
|
-
-
- HY-P5370
-
|
Amyloid-β
|
Others
|
Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)
|
-
-
- HY-P5333A
-
UB311 immunogen I acetate
|
Amyloid-β
|
Neurological Disease
|
Aβ1-14-εK-KKK-MvF5 Th acetate is the acetate salt form of Aβ1-14-εK-KKK-MvF5 Th (HY-P5333). Aβ1-14-εK-KKK-MvF5 Th acetate is part of UB-311 vaccine, that targets the amyloid-beta (Aβ) protein, and ameliorates the Alzheimer’s disease .
|
-
-
- HY-158978
-
|
Cholinesterase (ChE)
Monoamine Oxidase
|
Neurological Disease
|
Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC50=0.14 μM), butyrylcholinesterase (BChE, IC50=11.6 μM), monoamine oxidase B (MAO B, IC50=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4883
-
-
- HY-P4884
-
-
- HY-P4887
-
-
- HY-P4892
-
-
- HY-P4894
-
-
- HY-P3793
-
|
Amyloid-β
|
Neurological Disease
|
Amyloid β-Protein (33-42) TFA is the residues 33-42 fragment of the β-amyloid protein. Amyloid β-Protein (33-42) TFA inhibits Aβ42-induced toxicity .
|
-
- HY-P4881
-
|
Peptides
|
Others
|
Amyloid β-Protein (1-24) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P4879
-
|
Peptides
|
Others
|
Amyloid β-Protein (1-12) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P4886
-
|
Amyloid-β
|
Neurological Disease
|
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .
|
-
- HY-P1474
-
Amyloid β-protein (22-35)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35), the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P1051
-
Amyloid β-protein (12-28)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .
|
-
- HY-P1474A
-
Amyloid β-protein (22-35) (TFA)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid 22-35 (Amyloid β-Protein 22-35) TFA, the residues 22-35 fragment ofβ-amyloid protein, has a cytotoxic effect on cultured neurons from the rat hippocampus in serum-free medium. β-Amyloid 22-35 TFA forms aggregates and typical amyloid fibrils resembling those of the β-amyloid protein in neutral buffer solution) .
|
-
- HY-P1051A
-
Amyloid β-protein (12-28) (TFA); Amyloid Beta-Peptide (12-28) (human) TFA; β-Amyloid protein fragment(12-28) TFA
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research .
|
-
- HY-P1046
-
Amyloid β-protein (1-15)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
|
-
- HY-P1466
-
Amyloid β-protein (1-16)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
|
-
- HY-P1468
-
Amyloid β-protein (1-28)
|
Amyloid-β
|
Neurological Disease
|
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
|
-
- HY-P3858
-
|
Amyloid-β
|
Neurological Disease
|
(D-Asp1)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .
|
-
- HY-P4878
-
|
Peptides
|
Neurological Disease
|
5-TAMRA-Amyloid β-Protein (1-40) is a fluorescent (TAMRA)-labeled Amyloid β-Protein (1-40), Abs/Em=544/572 nm .
|
-
- HY-P3859
-
|
Amyloid-β
|
Neurological Disease
|
Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Cys-Gly-Lys-Arg-Amyloid β-Protein (1-42) can be used in research of Alzheimer's disease .
|
-
- HY-P4640
-
-
- HY-P3845
-
|
Amyloid-β
|
Neurological Disease
|
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation .
|
-
- HY-P3846
-
|
Amyloid-β
|
Neurological Disease
|
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .
|
-
- HY-P3860
-
-
- HY-P4888
-
|
Peptides
|
Neurological Disease
|
(Pyr11)-Amyloid β-Protein (11-40) (A beta 11pE-40) is a peptide. (Pyr11)-Amyloid β-Protein (11-40) can be used for the research of Alzheimer's disease .
|
-
- HY-P4585
-
|
Amyloid-β
|
Neurological Disease
|
(Gln22)-Amyloid β-Protein (1-42) is a Dutch mutation (E22Q) form of β-Amyloid (1-42) (HY-P1363). (Gln22)-Amyloid β-Protein (1-42) exhibits enhanced fibrillogenic and pathogenic properties .
|
-
- HY-P3781
-
|
Amyloid-β
|
Neurological Disease
|
(Met(O)35)-Amyloid β-Protein (1-42) is the oxidation form of Met35 in Aβ42. (Met(O)35)-Amyloid β-Protein (1-42) can yield an oligomer size distribution characteristic of Aβ40. (Met(O)35)-Amyloid β-Protein (1-42) can be used in the research of Alzheimer’s disease (AD) .
|
-
- HY-P4788
-
|
Amyloid-β
|
Neurological Disease
|
Acetyl-Amyloid β-Protein (1-6) amide is a hexapeptide that contains a potential copper(II) binding site. Acetyl-Amyloid β-Protein (1-6) amide can be used for research of Alzheimer's disease and related disorders .
|
-
- HY-P4882
-
|
Amyloid-β
|
Neurological Disease
|
(Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
|
-
- HY-P3783
-
-
- HY-P4893
-
|
Peptides
|
Cardiovascular Disease
|
(Gln22,Asn23)-Amyloid β-Protein (1-40) is a peptide. (Gln22,Asn23)-Amyloid β-Protein (1-40) can be used for the research of Cerebral Amyloid Angiopathy Mutations .
|
-
- HY-P4882A
-
|
Amyloid-β
|
Neurological Disease
|
(Pyr3)-Amyloid β-Protein (3-42) TFA is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) TFA is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
|
-
- HY-P4391
-
-
- HY-P4861
-
|
Amyloid-β
|
Others
|
Biotinyl-Ahx-Amyloid β-Protein (1-42) is abiotinylated β-Amyloid (1-42), human (TFA) (HY-P1363).
|
-
- HY-P3782
-
-
- HY-P1468F
-
Biotin-Amyloid β-protein (1-28)
|
Amyloid-β
|
Others
|
Biotin-β-amyloid (1-28) (Biotin-amyloid β-protein (1-28)) is abiotinylated β-Amyloid (1-28) (HY-P1468).
|
-
- HY-P3780
-
|
Amyloid-β
|
Neurological Disease
|
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .
|
-
- HY-P4719
-
|
Peptides
|
Others
|
(Val2)-Amyloid β-Protein (1-6) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P5096
-
|
Peptides
|
Others
|
FITC-β-Ala-Amyloid β-Protein (1-42) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P3908
-
|
Amyloid-β
|
Neurological Disease
|
FITC-β-Ala-Amyloid β-Protein (1-42) ammonium is a FITC tagged Aβ1-42 monomer peptide. Aβ1-42 plays a key role in the pathogenesis of Alzheimer’s disease .
|
-
- HY-P4889
-
|
Peptides
|
Neurological Disease
|
(Gly22)-amyloid beta-protein(1-40) (Arctic variant Ab40ARC (E22G)) is a peptide. (Gly22)-amyloid beta-protein(1-40) can be used for the research of Alzheimer's disease .
|
-
- HY-P1468F1
-
5-FAM-Amyloid β-protein (1-28)
|
Amyloid-β
|
Others
|
5-FAM-β-Amyloid (1-28) is afluorescently labeled β-Amyloid (1-28) (HY-P1468).
|
-
- HY-P2551
-
|
Amyloid-β
|
Neurological Disease
|
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-?-(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via?post-translational processing of amyloid precursor protein (APP) .
|
-
- HY-P10040
-
|
Peptides
|
Neurological Disease
|
(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .
|
-
- HY-P1522
-
-
- HY-P5331
-
|
Peptides
|
Others
|
[Asn23]-beta-Amyloid (1-42), iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
|
-
- HY-P5365
-
|
Peptides
|
Others
|
[Asn23] β-Amyloid (1-40), Iowa mutation is a biological active peptide. (Several mutations in the beta amyloid precursor gene cause autosomal dominant Alzheimer's Disease in a number of kindreds. The Iowa mutation, where Asp 23 is replaced with Asn, is associated with severe cerebral amyloid beta-protein angiopathy (CAA). The affected individuals share a missense mutation in APP at position 694. The mutated beta-amyloid peptide aggregates more rapidly and forms toxic fibrils.)
|
-
- HY-P5370
-
|
Amyloid-β
|
Others
|
Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)
|
-
- HY-P5333A
-
UB311 immunogen I acetate
|
Amyloid-β
|
Neurological Disease
|
Aβ1-14-εK-KKK-MvF5 Th acetate is the acetate salt form of Aβ1-14-εK-KKK-MvF5 Th (HY-P5333). Aβ1-14-εK-KKK-MvF5 Th acetate is part of UB-311 vaccine, that targets the amyloid-beta (Aβ) protein, and ameliorates the Alzheimer’s disease .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: